GVHD

Disease

Disease Profile

GVHD stands for graft-versus-host disease, an alloimmune complication after allogeneic stem-cell or bone marrow transplantation in which donor immune cells attack recipient tissues. It can present as acute or chronic disease with multisystem involvement. GVHD is a major determinant of post-transplant morbidity and mortality.

Category: Post-transplant alloimmune syndrome
Prevalence: About one-third to one-half of allogeneic transplant recipients develop acute GVHD

ICD Codes

D89.81

Related News

Off-the-Shelf CAR-T Therapy CB-011 Shows High Response Rates in Multiple Myeloma; Broader CAR-T Advances Presented at 2026 Tandem Meetings

Jun 09, 2026

Updated data from the phase I CaMMouflage trial showed CB-011, the first allogeneic anti-BCMA CAR-T therapy with immune cloaking, achieved an approximately 92% overall response rate in relapsed/refractory multiple myeloma. The 2026 Tandem Meetings also highlighted advances in EB-103, KITE-753, and LV20.19 CAR-T constructs across lymphoma and CLL. Separately, NXC-201 reported a 95% complete response rate in AL amyloidosis.

Novel GVHD Prevention Regimen Shows Strong Results Without Standard Immunosuppressants

Mar 25, 2026

Interim results from the ABC phase 1/2b trial show a calcineurin inhibitor-free GVHD prevention regimen combining posttransplant cyclophosphamide, bortezomib, and abatacept achieved low GVHD rates and favorable survival outcomes. The approach enables earlier introduction of posttransplant maintenance therapies while reducing toxicity associated with conventional immunosuppressants.

AI Tool Predicts Life-Threatening Transplant Complications Months Before Symptoms Appear

Feb 17, 2026

Researchers developed BIOPREVENT, an AI-based tool that predicts chronic graft-versus-host disease and transplant-related mortality in stem cell and bone marrow transplant patients by analyzing blood biomarkers and clinical data collected 90-100 days post-transplant.

CAR-T Therapy Advances and Nanoparticle Immunotherapy Show Promise in Cancer Treatment

Feb 15, 2026

CAR-T cell therapy engineering advances at Tandem 2026 focus on reducing toxicity and improving access, while McGill researchers develop targeted nanoparticle immunotherapy for lymph node metastases with fewer side effects.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07570407	Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation	NOT_YET_RECRUITING
NCT07508345	Endothelial Dysfunction as a Predictive Marker of Acute Graft-Versus-Host Disease in Adult Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	COMPLETED
NCT07314892	Psychiatric Status and Symptom Severity in Graft-versus-Host Disease (GvHD).	RECRUITING
NCT07302776	TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT	NOT_YET_RECRUITING	PHASE1
NCT07014059	Autologous Serum Obtained by a Closed-Circuit Collection Device	NOT_YET_RECRUITING	PHASE2
NCT06995521	Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population	NOT_YET_RECRUITING	PHASE2
NCT06938165	The Safety and Efficacy of Fecal Microbiota Transplant (FMT) for Steroid-refractory Graft-versus-host Disease	COMPLETED	NA
NCT06590285	Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation	RECRUITING	NA
NCT06469411	Effect of PMSCs and Their Secretome for the Treatment of GvHD	COMPLETED	PHASE3
NCT06462365	Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)	RECRUITING	PHASE1